# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

# FORM 8-K

CURRENT REPORT

### PURSUANT TO SECTION 13 OR 15(d) OF THE **SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): November 9, 2023

Commission file number 001-39531

PROCESSA PHARMACEUTICALS, INC.  (Exact name of Registrant as Specified in its Charter)		
(Exact na	tine of Registrant as Specified in its	
Delaware (State or Other Jurisdiction of		45-1539785
(State of Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification Number)
7380 Coca 0	Cola Drive, Suite 106, Hanover, Ma	aryland 21076
	Principal Executive Offices, Includ	
	(443) 776-3133	
(Registra	nt's Telephone Number, Including	Area Code)
(Former Name	e or Former Address, if Changed Si	nce Last Report)
Check the appropriate box below if the Form 8-K filing is intended to	simultaneously satisfy the filing obli	gation of the registrant under any of the following provisions:
$\hfill \Box$ Written communications pursuant to Rule 425 under the Securities	es Act (17 CFR 230.425)	
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange	Act (17 CFR 240.14a-12)	
$\ \square$ Pre-commencement communications pursuant to Rule 14d-2(b) $\iota$	under the Exchange Act (17 CFR 240	.14d-2(b))
$\ \square$ Pre-commencement communications pursuant to Rule 13e-4(c) u	under the Exchange Act (17 CFR 240.	.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:		
Title of each class Common stock: Par value \$.0001	Trading symbol(s) PCSA	Name of each exchange on which registered  Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).	company as defined in Rule 405 of t	the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
Emerging growth company $\square$		
If an emerging growth company, indicate by check mark if the reaccounting standards provided pursuant to Section 13(a) of the E		ended transition period for complying with any new or revised financial
Item 5.02 Departure of Directors or Certain Officers; Election of	Directors; Appointment of Certain	Officers; Compensatory Arrangements of Certain Officers
ad incorporated herein by reference, announcing that Virgil Thom	pson, age 83, a member of the Cor	which is attached as Exhibit 99.1 to this Current Report on Form 8-K mpany's Board of Directors and Chairman of our Nominating and not have immediate plans to appoint a new member to our Board of
Item 9.01. Financial Statements and Exhibits.		

Cover Page Interactive Data File (embedded within the iXBRL (Inline eXtensible Business Reporting Language) document).

(d) Exhibits

99.1

104

The following exhibit is filed herewith:


Press Release dated November 13, 2023

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on November 13, 2023.

PROCESSA PHARMACEUTICALS, INC. Registrant

By: /s/ George Ng
George NG
Chief Executive Officer



#### Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Hanover, MD. (Global Newswire) – Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023. Mr. Thompson served on our Board of Directors since we were formed in 2017 and was previously on the Board of Directors of Promet Therapeutics, LLC, our predecessor. He was 83 years old.

"We are all saddened by the sudden passing of our friend and one of our founding board members, Virgil Thompson," commented Justin Yorke, Chairman of Processa's Board of Directors. "We are thankful for Virgil's leadership, guidance and wisdom, and we will remember him fondly. He will be greatly missed by the Board and the whole Processa family." Over his career Mr. Thompson's experiences included servicing as an executive and/or director for several biotechnology companies.

#### About Processa Pharmaceuticals, Inc.

Processa is a clinical stage pharmaceutical company focused on developing the Next Generation Chemotherapy drugs to improve the safety and efficacy of cancer treatment. By combining Processa's novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also increase the probability of FDA approval for its Next Generation Chemotherapy drugs. Processa's NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Our approach to drug development is based on more than 30 years of drug development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. Using its proven Regulatory Science Approach, we have experience defining the Optimal Dosage Regimen using the principles of the FDA's Project Optimus Oncology initiative. The advantages of Processa's Next Generation Chemotherapy drugs are expected to include fewer patients experiencing side effects that lead to dose discontinuation; more significant cancer response; and a greater number of patients who will benefit from each Next Generation Chemotherapy drug. Currently in our pipeline are three Next Generation Chemotherapy drugs: Next Generation Capecitabine (PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers), and Other cancers), and Other cancers).

For more information, visit our website at www.processapharma.com.

#### For More Information:

#### **Investors:**

Bret Shapiro CORE IR ir@processapharma.com

#### Company Contact:

Patrick Lin (925) 683-3218 plin@processapharma.com